ITOS (ITeos Therapeutics) Total Inventories : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics Total Inventories?

ITeos Therapeutics's total inventories for the quarter that ended in Mar. 2025 was $0.00 Mil. ITeos Therapeutics's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Mar. 2025 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ITeos Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was $11.10.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ITeos Therapeutics Total Inventories Historical Data

The historical data trend for ITeos Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Total Inventories Chart

ITeos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

ITeos Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

ITeos Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

ITeos Therapeutics (NAS:ITOS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ITeos Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is

	Net-Net Working Capital Per Share (Q: Mar. 2025 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(520.369	+	0.75 * 0	+	0.5 * 0	-	95.447
-	0	-	0)	/	38.272
=	11.10

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ITeos Therapeutics's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2025 )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ITeos Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2025 )	/	Average Total Inventories (Q: Mar. 2025 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ITeos Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

ITeos Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

ITeos Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Watertown, MA, USA, 02472

Website

https://www.iteostherapeutics.com

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Executives

Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Matthew Gall	officer: Chief Financial Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux	director, officer: Chief Executive Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath	officer: VP, Research and Development	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager	officer: Chief Medical Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p.	other: X*	450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho	director	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139